Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06504017

FUS-TB VS COG-TB in Small Lesions of Prostate Cancer

To compare the positive detection rates of COG-TB vs FUS-TB for prostate cancer with PI-RADS 4 small lesions.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Prostate cancer (PCA) is the most frequent malignancy in male urogenital system. According to the World Health Organization's 2020 GLOBOCAN statistics, there are approximately 1.4 million new cases and 375,000 deaths worldwide. PCa is the second most common tumor in male patients after lung cancer and ranks fifth among cancer causes of death.

Currently, prostate specific antigen ( PSA ), digital rectal examination (DRE), multi-parametric magnetic resonance imaging (mpMRI), prostate specific membrane antigen positron emission Tomography/computed tomography (PSMA PET/CT) and other detection methods have played an important role in the diagnosis of PCa, but the gold standard for confirming PCa is the histopathological examination of prostate biopsy. Performing mpMRI before biopsy can help detect and locate prostate cancer with ISUP grade ≥2. Studies have shown that the prostate imaging reporting and data system (PI-RADS) may help improve the detection of clinically significant cancers. Biopsy should be considered when PI-RADS score 4 or 5.

This clinical study intends to use the mpMRI-TRUS image fusion ultrasound system to assist in guiding FUS-TB, comparing to COG-TB to evaluate the application value of mpMR-TRUS image fusion in the detection of PCa in prostate biopsy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1) male who are between 18 to 80 years old; 2) meet any of the following criteria:
  • suspicious nodules of prostate under digital rectal examination(DRE), with any PSA value;
  • PSA≥10μg/L;
  • 4μg/L≤PSA<10μg/L,f/t PSA≤0.16; 3) suspicious lesions under mpMRI, at least one lesion <5mm, PI-RADS 4; 4) good compliance; 5) must sign the informed consent form.

Exclusion criteria

  • 1) diagnosed prostate cancer or acute prostatitis; 2) acute infection, or clinically significant urinary tract infection; 3) performed prostate puncture within 1 month; 4) cardiac insufficiency; 5) having high risk of bleeding or taking anticoagulants for a long time; 6) severe internal or external hemorrhoids, perianal or rectal lesions; 7) having severe osteoarticular diseases that can not be performed lithotomy; 8) hypertensive crisis; 9) patients who should not be anesthetized; 10) patients with mental illness or mental disorders and unable to understand the informed consent; 11) patients with electronic devices such as built-in artificial pacemaker, cochlear implants or nerve stimulators; 12) other surgical contraindications, or those considered unsuitable by the investigators.

Treatment and study plan

COG-TB: Cognitive Fusion guided prostate targeted Biopsy

Procedure

Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound

FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy

Procedure

MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound

Primary outcomes

  1. detection rate of any PCa

    Time frame: 1 week (after pathology)

    detection rate of any prostate cancer

Secondary outcomes

  1. detection rate(cs PCa and PCa) of TBx

    Time frame: 1 week (after pathology)

    detection rate for PI-RADS 4 small lesion (<5mm) under MRI-TRUS fusion

Study contacts

Contact information is provided by the study sponsor or research team.

Shangqian Wang, PhD

CONTACT

[email protected]

0086-025-68306360

Xu Wang

CONTACT

[email protected]

0086-025-68306360

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University

Other

Collaborators

  • Huai'an First People's Hospital

Registry information

Official study title

FUS-TB VS COG-TB in Prostate Cancer With PI-RADS 4 Small Lesions - a Predictive, Multi-center, Exploring Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 16, 2024
Registry last updated
Jul 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.